BioSpace News Archive

Amgen (NASDAQ:AMGN) will present at the Bank of America Virtual Global Healthcare Conference at 12:35 p.m. ET on Thursday, Sept. 17, 2020.

Hologic, Inc. (Nasdaq: HOLX) announced today that it has priced its previously announced private offering of $950 million aggregate principal amount of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000.

Pharma-Bio Serv, Inc. (“Pharma-Bio Serv” or the “Company”) (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm that provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries, today announced it has filed its Quarterly Report on Form 10-Q for the quarter ended July 31, 2020.

Montefiore Medical Center announced that it is mailing letters to some patients alerting them of a data security breach involving one of its vendors, Blackbaud, Inc.

Biocom, the association representing the life science industry of California, issued the following statement in response to the drug pricing executive order signed by President Donald Trump yesterday.

SanBio Co., Ltd. hereby announces that it has obtained new analytical results from the Phase 2b clinical trial of SB623 for the treatment of chronic motor deficit resulting from ischemic stroke the SanBio Group conducted in the US.

Vertex Pharmaceuticals Incorporated announced the European Medicines Agency has validated a Type II Variation Marketing Authorization Application for the expanded indication of KAFTRIO®* in combination with ivacaftor to treat CF in patients ages 12 years and older with at least one copy of the F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Innovent Biologics, Inc. and Eli Lilly and Company jointly announce that results of six clinical studies of TYVYT® will be presented during the upcoming European Society of Medical Oncology Virtual Congress 2020 from September 19th to 21st.

Post Acute Medical, LLC announced that it has deployed Integrated Viral Protection’s indoor biodefense system at three of its specialty hospital locations in Las Vegas, Nevada, Victoria, Texas, and San Antonio, Texas as part of the company’s commitment to delivering important health services safely.

Seneca Therapeutics, Inc., a clinical-stage biopharmaceutical company dedicated to the development of oncolytic immunotherapeutics for cancer based on Seneca Valley Virus, announced the receipt of positive guidance from the FDA on the reactivation of the SVV-001 IND and Phase I/II protocol.